Journal of Current and Advance Medical Research
January 2025, Vol. 12, No. 1, pp. 54-55
http://www.banglajol.info/index.php/JCAMR
ISSN (Print) 2313-447X
ISSN (Online) 2413-323X
NLM Catalog ID 101673828
DOI: https://doi.org/10.3329/jcamr.v12i1.91760

Correspondence

Mandatory Sequential Testing and Age-Adjusted Thresholds in Guillain-Barré Syndrome Subtyping

Sanjida Hossain

Assistant Professor, Department of Microbiology, Dr. Sirajul Islam Medical College, Dhaka, Bangladesh

Guillain-Barré Syndrome (GBS) remains a medical emergency where rapid, precise diagnostics directly dictate critical intensive care interventions and immunotherapies. For decades, clinicians have relied heavily on a single, early-stage electrodiagnostic evaluation and baseline lumbar puncture to distinguish between the Acute Inflammatory Demyelinating Polyneuropathy (AIDP) and Acute Motor Axonal Neuropathy (AMAN) subtypes. However, emerging evidence, including a notable cross-sectional cohort of 108 patients in Bangladesh, reveals significant demographic, biochemical, and hematological variations across these variants—such as significantly higher mean ages in demyelinating presentations and hepatic enzyme spikes in axonal groups[1]. Relying purely on initial static laboratory values introduces severe clinical confounding variables, as failing to account for dynamic physiological evolution compromises diagnostic accuracy.

Current State of the Art

Traditional diagnostic algorithms prioritize differentiating AIDP from AMAN using initial nerve conduction studies (NCS) and the detection of albuminocytological dissociation (ACD) in cerebrospinal fluid (CSF). Recent epidemiological data highlights clear phenotype boundaries. The demyelinating variant demonstrates a significantly older patient profile like mean age 40.20 years compared to the younger demographic seen in the axonal variant like mean age 32.43 years[1]. Concurrently, systemic differences appear in routine panels, with elevated serum alanine aminotransferase (ALT/SGOT) frequently characterizing the axonal subpopulation[1]. While these associations provide invaluable epidemiological insight, treating them as static diagnostic markers oversimplifies a highly fluid, time-dependent autoimmune progression.

Critical Analysis & The Core Argument

The central flaw in current clinical frameworks is the diagnostic reliance on early, single-point testing.

Timing as an Important Confounding variable: Albumino-cytological dissociation is notoriously absent in 30.0% to 50.0% of GBS patients during the first week of symptom onset, only peaking later in the disease course[2]. An early lumbar puncture yielding normal protein levels frequently leads to delayed treatment or misdiagnosis.

Age Confound: Age is an important confounder when interpreting cerebrospinal fluid (CSF) protein levels because the blood-brain barrier becomes progressively more permeable with advancing age, resulting in physiologically higher baseline CSF protein concentrations independent of acute polyneuropathy. Consequently, applying a single fixed reference range across all age groups may introduce both statistical and clinical bias. For example, comparing CSF protein levels between a 20-year-old patient with AMAN and a 60-year-old patient with AIDP without age-adjusted reference values may lead to inaccurate interpretation and potentially confound study findings.

Electrodiagnostic Trap: Early nerve conduction studies often capture transient conduction blocks

that masquerade as demyelination, when the underlying pathology is inherently axonal[4].

Future Horizons and Clinical Implications

Achieving precision diagnostics in acute inflammatory neuropathies requires a shift from static, single-time-point testing to dynamic, sequential diagnostic strategies. Because cerebrospinal fluid (CSF) protein levels evolve throughout the disease course, repeat lumbar puncture in initially equivocal cases should be considered when clinically appropriate to improve diagnostic accuracy. Integrating serial CSF analysis with clinical assessment, electrophysiological studies, and emerging biomarkers may enhance subtype differentiation, reduce diagnostic uncertainty, and facilitate timely treatment. Future clinical guidelines should incorporate evidence-based recommendations for sequential testing, ensuring that diagnostic algorithms reflect the temporal nature of disease pathophysiology and support more individualized patient care.

Mandatory Serial NCS: Centers must mandate a repeat electrodiagnostic study 10 to 14 days post-onset to track the true kinetics of Wallerian degeneration and correct early diagnostic errors[4].

Regional, Age-Adjusted Thresholds: Research must establish standardized, regional, and age-stratified reference ranges for CSF protein profiles[3].

Integrated Biomarker Matrices: Rather than evaluating hematological, biochemical, and electrophysiological indicators in isolation, future protocols should combine these metrics into an integrated diagnostic matrix[1]. This approach will use age-weighting and enzyme trends to flag early sub-clinical axonal damage.

Conclusion

Differentiating GBS subtypes is not a binary checklist but a time-dependent, age-influenced puzzle. Transitioning to mandatory sequential tracking and age-adjusted thresholds will eliminate early false negatives, optimize resource distribution, and ensure that targeted immunotherapies are deployed safely and effectively when they matter most.

References

1. Islam MZ, Ara A, Yusuf MA, Karim R, Hussain ME, Moureen A, Shaikh MI. Hematological Parameters, Biochemical Findings and Cerebrospinal Fluid Profiles among Guillan-Barre Syndrome Patients. Journal of Current and Advance Medical Research. 2024;11(2):88-96.
2. Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014;137(1):33-43.
3. Seyfert S, Kunzmann V, Schwertfeger N, Koch HC, Fassbender K. Age-dependent profiles of CSF total protein and albumin. Acta Neurol Scand. 2004;109(2):128-132.
4. Hadden RD, Cornblath DR, Hughes RA, Asbury AK, Griffin JW, McKhann GM, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Ann Neurol. 1998;44(5):780-788.

[Journal of Current and Advance Medical Research, January 2025;12(1):54-55]

Correspondence: Dr. Sanjida Hossain, Assistant Professor, Department of Microbiology, Dr. Sirajul Islam Medical College, Dhaka, Bangladesh; **Email:** doc.sanjida@gmail.com; **Cell No.:** +8801705-051500; **ORCID**: https://orcid.org/0009-0003-2610-1862